The global drug discovery informatics market was valued approximately US$ 2.0 Bn in 2016 and is anticipated to register CAGR of over 17.0% from 2017 to 2025 to reach value of approximately US$ 7.8 Bn by 2025, according to a new market report published by Transparency Market Research (TMR) titled “Drug Discovery Informatics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”. The report suggests that the cost and time of drug discovery are reduced to a very large extent in comparison with the traditional drug discovery process are spur the demand of drug discovery informatics in the coming years (2017 to 2025). As key players introduce their drug discovery using informatics in developed markets such a North America and Western Europe, these regions are likely to account for dominating share of the global drug discovery informatics market. The increasing number of uses of the drug discovery informatics such as the scientists use it to communicate their ideas with their colleagues in computational chemistry, and biology to design small parallel libraries, and to conduct their own preliminary analysis of interactions between the ligand and receptor in emerging markets such as China and India is likely to boost growth of Asia Pacific drug discovery informatics market at a CAGR of around 20.0% from 2017 to 2025.
Get Report Sample @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=33713
Dearth of skilled and experienced professionals to Restrain Global Market Expansion
The rising laboratory informatics such as sharing, and searching of digital discovery information, and electronic lab notebook for the improved storage are driving the growth of the drug discovery informatics. The technological advancements in the drug discovery informatics that are employed by computational informatics are leading to developments in scientific innovation. The cost and time of drug discovery are reduced to a very large extent that drive the growth of the global drug discovery informatics market. However, there are only a few institutions and organizations in the world to train on drugs discovery informatics; moreover, the related experience is low in trained professionals, which in turn has attributed for devaluation of the market, there by restraining growth of global drug discovery informatics market.
Discovery Informatics to Be the Most Promising Product Type to Invest in
The Global Drug Discovery Informatics Market is classified on the basis of product, mode, function, end-user, and region. Based on the product, the market is divided into development informatics, and discovery informatics. The discovery informatics segment dominated the market in terms of revenue in 2016, due to its cost benefits. Development informatics is anticipated to grow during the forecast period owing to the technological advancements in the development informatics. In terms of mode the market can be categorized into outsourced informatics, and in-house informatics. Outsourced informatics is estimated to dominate in terms of revenue in 2016 owing to the rise in collaborations and lead drug discovery projects between pharmaceutical companies, and IT market participants. In-house informatics is anticipated to grow in the coming years due to rise in the awareness regarding the time and cost benefits in the long run for the biotechnological and pharmaceutical companies.
Pharmaceutical & Biotechnology Companies to gain Market Share
Based on function the market can be classified into sequencing and target data analysis, docking, lead generation informatics, identification & validation informatics, molecular modeling, and others. Sequencing and target data analysis is estimated to dominate the market in 2016, owing to reduced cost of sequencing informatics. Molecular modeling segment is anticipated to grow during the forecast period owing to the increasing number of applications of small molecules in drug discovery. In terms of end-user the market can be divided into contract research organizations, pharmaceutical & biotechnology companies, and others. Contract research organizations (CROs) segment is estimated to dominate in 2016, owing to increasing number of CROs all over the world for drug discovery. Pharmaceutical and biotechnological companies segment is anticipated to grow during the forecast period owing to the long term time and cost benefits of the drug discovery informatics.